S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PSTX

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

$3.19
+0.11 (+3.57%)
(As of 03/28/2024 ET)
Today's Range
$3.02
$3.24
50-Day Range
$2.76
$4.13
52-Week Range
$1.54
$4.27
Volume
697,679 shs
Average Volume
748,385 shs
Market Capitalization
$307.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

Poseida Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
359.8% Upside
$14.67 Price Target
Short Interest
Bearish
6.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.19mentions of Poseida Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.77) to ($1.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.28 out of 5 stars

Medical Sector

361st out of 938 stocks

Biological Products, Except Diagnostic Industry

51st out of 148 stocks

PSTX stock logo

About Poseida Therapeutics Stock (NASDAQ:PSTX)

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

PSTX Stock Price History

PSTX Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Poseida Therapeutics (NASDAQ:PSTX) Trading Down 2.3%
PSTX Apr 2024 5.000 put
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Poseida Therapeutics Inc Ordinary Shares
BTIG Keeps Their Buy Rating on Poseida Therapeutics (PSTX)
BTIG Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
See More Headlines
Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PSTX
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.67
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+359.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-123,430,000.00
Net Margins
-190.76%
Pretax Margin
-190.60%

Debt

Sales & Book Value

Annual Sales
$64.70 million
Book Value
$1.08 per share

Miscellaneous

Free Float
94,463,000
Market Cap
$307.80 million
Optionable
Optionable
Beta
0.39
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark J. Gergen J.D. (Age 61)
    Executive Chairman of the Board
    Comp: $920.74k
  • Mr. Harry J. Leonhardt Esq. (Age 67)
    J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $630.23k
  • Mr. Brent Warner (Age 39)
    President of Gene Therapy
    Comp: $835.93k
  • Dr. Kristin Yarema Ph.D. (Age 52)
    President, CEO & Director
  • Ms. Johanna M. Mylet CPA (Age 36)
    Chief Financial Officer
  • Mr. Loren Wagner
    Chief Operations Officer
  • Ms. Kristin Martin
    Chief People & Administration Officer
  • Mr. Alexander Chapman
    Senior VP of Investor Relations & Corporate Communications
  • Dr. Devon J. Shedlock Ph.D.
    Chief Scientific Officer of Cell Therapy
  • Ms. Lisa Portale
    Senior Vice President of Regulatory Affairs

PSTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Poseida Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTX shares.
View PSTX analyst ratings
or view top-rated stocks.

What is Poseida Therapeutics' stock price target for 2024?

3 brokerages have issued 12 month price objectives for Poseida Therapeutics' shares. Their PSTX share price targets range from $10.00 to $20.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 359.8% from the stock's current price.
View analysts price targets for PSTX
or view top-rated stocks among Wall Street analysts.

How have PSTX shares performed in 2024?

Poseida Therapeutics' stock was trading at $3.36 on January 1st, 2024. Since then, PSTX shares have decreased by 5.1% and is now trading at $3.19.
View the best growth stocks for 2024 here
.

When is Poseida Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PSTX earnings forecast
.

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.09. The firm had revenue of $25 million for the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 94.90% and a negative net margin of 190.76%.

What ETFs hold Poseida Therapeutics' stock?

ETFs with the largest weight of Poseida Therapeutics (NASDAQ:PSTX) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA).Global X Genomics & Biotechnology ETF (GNOM).

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).

When did Poseida Therapeutics IPO?

Poseida Therapeutics (PSTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

Who are Poseida Therapeutics' major shareholders?

Poseida Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.03%), Vanguard Group Inc. (3.00%), Northern Trust Corp (0.58%), Charles Schwab Investment Management Inc. (0.53%), Dimensional Fund Advisors LP (0.51%) and Goldman Sachs Group Inc. (0.49%). Insiders that own company stock include Eric Ostertag, Kerry D Ingalls, Life Sciences Holdings L Malin and Matthew A Spear.
View institutional ownership trends
.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners